Akorn Inc. (NASDAQ:AKRX)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $31.68, but opened at $31.80. Akorn shares last traded at $32.32, with a volume of 386,927 shares changing hands.

Several equities analysts have recently commented on AKRX shares. Zacks Investment Research cut shares of Akorn from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Leerink Swann restated a “hold” rating on shares of Akorn in a research report on Thursday, May 26th. TheStreet upgraded shares of Akorn from a “hold” rating to a “buy” rating in a research report on Wednesday, May 11th. Royal Bank Of Canada reiterated a “buy” rating on shares of Akorn in a research report on Monday, July 18th. Finally, RBC Capital Markets reiterated an “outperform” rating and set a $37.00 price objective on shares of Akorn in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. Akorn has an average rating of “Buy” and a consensus price target of $34.46.

The firm has a market capitalization of $3.89 billion and a PE ratio of 25.96. The stock’s 50-day moving average is $30.04 and its 200 day moving average is $27.35.

Akorn (NASDAQ:AKRX) last posted its earnings results on Monday, May 16th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.11. During the same period last year, the firm earned $0.16 EPS. The business earned $268 million during the quarter. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities analysts predict that Akorn Inc. will post $2.16 earnings per share for the current year.

In other news, SVP Joseph Bonaccorsi sold 90,250 shares of the firm’s stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $31.23, for a total value of $2,818,507.50. Following the completion of the transaction, the senior vice president now directly owns 470,862 shares in the company, valued at $14,705,020.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kenneth Abramowitz sold 14,675 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $30.16, for a total transaction of $442,598.00. Following the completion of the transaction, the director now owns 33,185 shares of the company’s stock, valued at $1,000,859.60. The disclosure for this sale can be found here.

Several institutional investors have recently added to or reduced their stakes in AKRX. Gamco Investors INC. ET AL raised its position in Akorn by 5.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 31,100 shares of the company’s stock worth $1,160,000 after buying an additional 1,600 shares during the period. Mutual of America Capital Management LLC raised its position in Akorn by 3.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 54,788 shares of the company’s stock worth $2,044,000 after buying an additional 1,763 shares during the period. I.G. Investment Management LTD. raised its position in Akorn by 5.7% in the fourth quarter. I.G. Investment Management LTD. now owns 85,620 shares of the company’s stock worth $3,194,000 after buying an additional 4,590 shares during the period. Comerica Bank raised its position in Akorn by 3.3% in the fourth quarter. Comerica Bank now owns 88,358 shares of the company’s stock worth $3,311,000 after buying an additional 2,818 shares during the period. Finally, Rhumbline Advisers raised its position in Akorn by 1.4% in the fourth quarter. Rhumbline Advisers now owns 174,542 shares of the company’s stock worth $6,512,000 after buying an additional 2,330 shares during the period.

Akorn Inc (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.